Recombinant Human IL-36 alpha/IL-1F6 Protein, CF

• Reactivity: Hu
• Applications: Binding Activity
• Format: Carrier-Free

Recombinant Human IL-36 alpha/IL-1F6 Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. Immobilized recombinant human IL-36 alpha at 1 µg/mL (100 µL/well) can bind recombinant human IL-1 Rrp2 Fc Chimera (Catalog # 872-RP) with a linear range of 0.15-5 µg/mL.
• Source: E. coli-derived human IL-36 alpha/IL-1F6 protein
  Met1-Phe158
• Accession #: Q9UHA7
• N-terminal Sequence: Met
• Protein/Peptide Type: Recombinant Proteins
• Gene: IL36A
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <1.0 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Binding Activity
• Theoretical MW: 17.7 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS, NaCl and Tween® 20.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

Tween is a registered trademark of ICI Americas.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IL-36 alpha/IL-1F6 Protein, CF

• FIL1 epsilon
• FIL1
• FIL1(EPSILON)
• FIL1E
• IL-1 epsilon
• IL1(EPSILON)
• IL1E
• IL-1E
• IL-1F6 (FIL-1-epsilon)
• IL1F6
• IL-1F6
• IL36 alpha
• IL-36 alpha
• IL36A
• interleukin 1 family, member 6 (epsilon)
• interleukin 1, epsilon
• Interleukin 36, Alpha
• Interleukin-1 epsilon
• interleukin-1 family member 6
• Interleukin-36 Alpha

Background

Human interleukin‑36 alpha [IL‑36 alpha ; previously IL‑1F6 and also FIL‑1 epsilon  (epsilon)] is a member of the IL‑1 family of proteins (1 ‑ 3, 6). IL‑1 family members include IL‑1 beta , IL‑1 alpha , IL‑1ra, IL‑18, IL‑36Ra/IL‑1F5, IL‑37/IL‑1F7, IL‑36 beta /IL‑1F8, IL‑36 gamma /IL‑1F9 and IL‑1F10 (4, 6). All family members show a 12 beta ‑strand, beta ‑trefoil configuration, and all family members are believed to have arisen from a common ancestral gene that has undergone multiple duplications (4). IL‑36 alpha /IL‑1F6 is synthesized as a 158 amino acid (aa) protein that contains no signal sequence, no prosegment and no potential N‑linked glycosylation site(s) (1 ‑ 3). It appears to be actively secreted (1). When found in cell lysate, it presents as an 18 kDa monomer (2). Human to mouse, full length IL‑1F6 has 54% aa identity. Within the family, IL‑1F6 is 30% aa identical to IL‑1ra, and 27%, 31%, 36%, 46%, 57% and 28% aa identical to IL‑1 beta , IL‑36Ra/IL‑1F5, IL‑37/IL‑1F7, IL‑36 beta /IL‑1F8, IL‑36 gamma /IL‑1F9 and IL‑1F10, respectively. Cells reported to express IL‑36 alpha /IL‑1F6 include monocytes, B cells and T cells (1, 4). Notably, IL‑36 alpha /IL‑1F6 is the only novel IL‑1 family member found to be expressed on T cells. The receptor for IL‑36 alpha /IL‑1F6 is reported to be a combination of IL‑1 Rrp2 and IL‑1 RAcP (5). Recombinant IL‑36 alpha /IL‑1F6, along with IL‑36 beta /IL‑1F8 and IL‑36 gamma /IL‑1F9, has been shown to act as an agonist by activating the pathway involving NF‑ kappa B and MAPK in an IL‑1 Rrp2 dependent manner. This suggests that IL‑36 alpha /IL‑1F6 may signal in a similar fashion to IL‑1 and IL‑18 in having a binding receptor which upon ligation, recruits a second receptor as a signaling component, forming an active heterodimeric receptor complex.

1. Smith, D.E. et al. (2000) J. Biol. Chem. 275:1169.
2. Kumar, S. et al. (2000) J. Biol. Chem. 275:10308.
3. Nicklin, M.J.H. et al. (2002) Genomics. 79:718.
4. Dunn, E. et al. (2001) Trends Immunol. 22:533.
5. Towne, J.E. et al. (2004) J. Biol. Chem. 279:13677.
6. Dinarello, C. et al. (2010) Nat. Immunol. 11:973.

Publications for IL-36 alpha/IL-1F6 (1078-IL/CF)(2)

Publications using 1078-IL/CF

• Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 2012-07-26;487(7408):505-9. 2012-07-26 [PMID: 22763448] (Bioassay, Human)
• Carrier Y, Ma HL, Ramon HE, Napierata L, Small C, O'Toole M, Young DA, Fouser LA, Nickerson-Nutter C, Collins M, Dunussi-Joannopoulos K, Medley QG Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J. Invest. Dermatol., 2011-09-01;131(12):2428-37. 2011-09-01 [PMID: 21881584] (Bioassay, Human)

Bioinformatics

• Gene Symbol: IL36A
• Uniprot:
  • Q9UHA7()